Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Metab Brain Dis. 2019 Aug 13;34(6):1705–1712. doi: 10.1007/s11011-019-00476-3

Fig. 2. Anti-PDL2 antibody treatment changes the male splenocyte subtypes, PDL1 and PDL2 expression but not in female mice.

Fig. 2

Treatment with an anti-PDL2 neutralizing antibody (n = 15) significantly decreased the frequency of PDL2 on CD19+ splenocytes compared to vehicle treated mice (n = 19) 96 h post-MCAO (a). There was also a significant decrease in the frequency of PDL1 on CD4+ splenocytes in the anti-PDL2 neutralizing antibody group (n = 15) compared to vehicle treated mice (b; n = 21). In the spleens of male mice treated with anti-PDL2 neutralizing antibody after MCAO (n = 15) there was a significant increase in the frequency of CD19+ cells compared to vehicle treated mice (c; n = 21). *p < 0.05; **p < 0.01